Literature DB >> 20380835

The role of macrophage-derived urokinase plasminogen activator in myocardial infarct repair: urokinase attenuates ventricular remodeling.

Elina Minami1, Chiara Castellani, Laura Malchodi, Jennifer Deem, Kate Bertko, Jessica Meznarich, Monja Dishmon, Charles E Murry, April Stempien-Otero.   

Abstract

Cardiac plasmin activity is increased following myocardial ischemia. To test the hypothesis that macrophage-derived uPA is a key mediator of repair following myocardial infarction, we performed myocardial infarction on mice with macrophage-specific over-expression of uPA (SR-uPA mice). SR-uPA(+/0) mice and wild-type littermates were sacrificed at 5 days or 4 weeks after infarction and cardiac content of macrophages, collagen, and myofibroblasts was quantified. Cardiac function and dimensions were assessed by echocardiography at baseline and at 4 weeks post-infarction. At 4 weeks after myocardial infarction, macrophage counts were increased in SR-uPA(+/0) mice in the infarct (13.1 vs. 4.9%, P<0.001) and distant uninfarcted regions (5.9 vs. 2.4%, P<0.001). Infarct scar was thicker in SR-uPA(+/0) mice (0.54+/-0.03 mm vs. 0.45+/-0.03 mm, P<0.05) and infarct cardiac collagen content was increased (72.4+/-3.3% vs. 63.0+/-3.6%, P<0.06). Functionally, these changes resulted in mildly improved fractional shortening in SR-uPA(+/0) mice compared to controls (24.6+/-1.68 vs. 19.8+/-1.3%, P=0.03). At 5 days after infarction there was increased collagen content in the scar without increases in macrophages or myofibroblasts. To understand the mechanisms by which macrophage-derived uPA increases collagen, cardiac fibroblasts were treated with macrophage-conditioned medium or plasmin and expression of ColIalpha1 measured by qPCR. Conditioned media from SR-uPA(+/0) or plasmin-treated non-transgenic macrophages but not plasmin alone increased collagen expression in isolated cardiac fibroblasts. We hypothesize that plasmin generation in the heart in response to injury may induce activation of macrophages to a profibrotic phenotype to allow rapid formation of collagenous scar. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20380835      PMCID: PMC3041515          DOI: 10.1016/j.yjmcc.2010.03.022

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  30 in total

1.  Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice.

Authors:  Sandra B Haudek; Ying Xia; Peter Huebener; John M Lee; Signe Carlson; Jeff R Crawford; Darrell Pilling; Richard H Gomer; JoAnn Trial; Nikolaos G Frangogiannis; Mark L Entman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-17       Impact factor: 11.205

Review 2.  Control of matrix metalloproteinase catalytic activity.

Authors:  Hyun-Jeong Ra; William C Parks
Journal:  Matrix Biol       Date:  2007-07-07       Impact factor: 11.583

3.  rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice.

Authors:  Paul Gregorevic; James M Allen; Elina Minami; Michael J Blankinship; Miki Haraguchi; Leonard Meuse; Eric Finn; Marvin E Adams; Stanley C Froehner; Charles E Murry; Jeffrey S Chamberlain
Journal:  Nat Med       Date:  2006-07-02       Impact factor: 53.440

4.  CCL2/Monocyte Chemoattractant Protein-1 regulates inflammatory responses critical to healing myocardial infarcts.

Authors:  Oliver Dewald; Pawel Zymek; Kim Winkelmann; Anna Koerting; Guofeng Ren; Tareq Abou-Khamis; Lloyd H Michael; Barrett J Rollins; Mark L Entman; Nikolaos G Frangogiannis
Journal:  Circ Res       Date:  2005-03-17       Impact factor: 17.367

5.  Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload.

Authors:  Hidenori Matsusaka; Tomomi Ide; Shouji Matsushima; Masaki Ikeuchi; Toru Kubota; Kenji Sunagawa; Shintaro Kinugawa; Hiroyuki Tsutsui
Journal:  Hypertension       Date:  2006-02-27       Impact factor: 10.190

6.  Macrophage depletion impairs wound healing and increases left ventricular remodeling after myocardial injury in mice.

Authors:  Machteld J van Amerongen; Martin C Harmsen; Nico van Rooijen; Arjen H Petersen; Marja J A van Luyn
Journal:  Am J Pathol       Date:  2007-03       Impact factor: 4.307

7.  The plasminogen-MMP system is more activated in the scar than in viable myocardium 3 months post-MI in the rat.

Authors:  Roger Gaertner; Marie-Paule Jacob; Fabrice Prunier; Eduardo Angles-Cano; Jean-Jacques Mercadier; Jean-Baptiste Michel
Journal:  J Mol Cell Cardiol       Date:  2004-12-09       Impact factor: 5.000

8.  Critical role of monocyte chemoattractant protein-1/CC chemokine ligand 2 in the pathogenesis of ischemic cardiomyopathy.

Authors:  Nikolaos G Frangogiannis; Oliver Dewald; Ying Xia; Guofeng Ren; Sandra Haudek; Thorsten Leucker; Daniela Kraemer; George Taffet; Barrett J Rollins; Mark L Entman
Journal:  Circulation       Date:  2007-02-06       Impact factor: 29.690

9.  Mechanisms of cardiac fibrosis induced by urokinase plasminogen activator.

Authors:  April Stempien-Otero; Abigail Plawman; Jessica Meznarich; Teja Dyamenahalli; Goro Otsuka; David A Dichek
Journal:  J Biol Chem       Date:  2006-03-22       Impact factor: 5.157

10.  The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions.

Authors:  Matthias Nahrendorf; Filip K Swirski; Elena Aikawa; Lars Stangenberg; Thomas Wurdinger; Jose-Luiz Figueiredo; Peter Libby; Ralph Weissleder; Mikael J Pittet
Journal:  J Exp Med       Date:  2007-11-19       Impact factor: 14.307

View more
  10 in total

1.  Systems analysis of gene ontology and biological pathways involved in post-myocardial infarction responses.

Authors:  Nguyen T Nguyen; Merry L Lindsey; Yu-Fang Jin
Journal:  BMC Genomics       Date:  2015-06-11       Impact factor: 3.969

2.  A central role of plasmin in cardiac injury initiated by fetal exposure to maternal anti-Ro autoantibodies.

Authors:  Paraskevi Briassouli; Marc K Halushka; Joanne H Reed; Yair Molad; Karen Fox-Talbot; Lucas Buyon; Edwin Guzman; Achiau Ludomirsky; Robert M Clancy; Jill P Buyon
Journal:  Rheumatology (Oxford)       Date:  2013-04-18       Impact factor: 7.580

3.  MMP28 promotes macrophage polarization toward M2 cells and augments pulmonary fibrosis.

Authors:  Sina A Gharib; Laura K Johnston; Isham Huizar; Timothy P Birkland; Josiah Hanson; Ying Wang; William C Parks; Anne M Manicone
Journal:  J Leukoc Biol       Date:  2013-08-20       Impact factor: 4.962

4.  Atherosclerosis and cardiac function assessment in low-density lipoprotein receptor-deficient mice undergoing body weight cycling.

Authors:  T S McMillen; E Minami; R C Leboeuf
Journal:  Nutr Diabetes       Date:  2013-06-24       Impact factor: 5.097

5.  Urokinase-type plasminogen activator and arthritis progression: contrasting roles in systemic and monoarticular arthritis models.

Authors:  Christine M De Nardo; Jason C Lenzo; Jarrad Pobjoy; John A Hamilton; Andrew D Cook
Journal:  Arthritis Res Ther       Date:  2010-10-25       Impact factor: 5.156

6.  Direct intercellular communications dominate the interaction between adipose-derived MSCs and myofibroblasts against cardiac fibrosis.

Authors:  Xiaokang Li; Hui Zhao; Chunxiao Qi; Yang Zeng; Feng Xu; Yanan Du
Journal:  Protein Cell       Date:  2015-08-14       Impact factor: 14.870

7.  Urokinase plasminogen activator induces pro-fibrotic/m2 phenotype in murine cardiac macrophages.

Authors:  Jessica Meznarich; Laura Malchodi; Deri Helterline; Stephen A Ramsey; Kate Bertko; Tabitha Plummer; Abigail Plawman; Elizabeth Gold; April Stempien-Otero
Journal:  PLoS One       Date:  2013-03-11       Impact factor: 3.240

8.  Nicorandil regulates the macrophage skewing and ameliorates myofibroblasts by inhibition of RhoA/Rho-kinase signalling in infarcted rats.

Authors:  Tsung-Ming Lee; Shinn-Zong Lin; Nen-Chung Chang
Journal:  J Cell Mol Med       Date:  2017-11-09       Impact factor: 5.310

9.  A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure.

Authors:  Iziah E Sama; Rebecca J Woolley; Jan F Nauta; Simon P R Romaine; Jasper Tromp; Jozine M Ter Maaten; Peter van der Meer; Carolyn S P Lam; Nilesh J Samani; Leong L Ng; Marco Metra; Kenneth Dickstein; Stefan D Anker; Faiez Zannad; Chim C Lang; John G F Cleland; Dirk J van Veldhuisen; Hans L Hillege; Adriaan A Voors
Journal:  Eur J Heart Fail       Date:  2020-04-03       Impact factor: 15.534

Review 10.  Therapeutics targeting the fibrinolytic system.

Authors:  Haili Lin; Luning Xu; Shujuan Yu; Wanjin Hong; Mingdong Huang; Peng Xu
Journal:  Exp Mol Med       Date:  2020-03-09       Impact factor: 8.718

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.